Clinical Trials Browser

Phase 1/2 × INDUSTRY × Imatinib Mesylate × Clear all

NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Phase 1/2 Completed

117 enrolled 18 charts

GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT00093639 2013-05-01

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00417807 2010-12-24

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Phase 1/2 Completed

Refractory Desmoplastic Small Round Cell Tumors